Company Analysis
Sign in

Kyntra Bio, Inc. (KYNB)

Nasdaq: KYNB · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 2002
Full chart Alerts Compare
Grade4.2
◀ Past 4.6● Present 4.1▶ Future 4.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

89 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kyntra Bio, Inc.’s names, not what it holds today.

Patents granted
89
89 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 2 in 2023
Applications published
141
1 of them in 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
FibroGen, Inc. a former name
US, as the owner printed on each patent
89 granted
95 published
FibroGen, Inc. a former name
named as the applicant on its applications, in US
0 granted
46 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 20, 202311,680,048Enhanced erythropoiesis and iron metabolismPharmaceuticalsFibroGen, Inc.
Jun 20, 202311,680,047Enhanced erythropoiesis and iron metabolismPharmaceuticalsFibroGen, Inc.
Apr 12, 202211,299,537Methods for treatment of motor neuron diseasesPharmaceuticalsFibroGen, Inc.
Jan 25, 202211,229,637Nitrogen-containing heteroaryl compounds and methods of use thereofPharmaceuticalsFibroGen, Inc.
Feb 23, 202110,927,081Enhanced erythropoiesis and iron metabolismPharmaceuticalsFibroGen, Inc.
Jan 19, 202110,894,774Enhanced erythropoiesis and iron metabolismPharmaceuticalsFibroGen, Inc.
Jan 5, 202110,882,827Enhanced erythropoiesis and iron metabolismPharmaceuticalsFibroGen, Inc.
Sep 8, 202010,765,672Pharmaceutical formulations of a HIF hydroxylase inhibitorPharmaceuticalsFibroGen, Inc.
May 12, 202010,646,482Nitrogen-containing heteroaryl compounds and methods of use thereofPharmaceuticalsFibroGen, Inc.
Apr 21, 202010,626,090Enhanced erythropoiesis and iron metabolismPharmaceuticalsFibroGen, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Mar 27, 20252025/0099455TREATMENT FOR CONGESTIVE HEART FAILUREPharmaceuticalsFibroGen, Inc.
Jun 6, 20242024/0182424ENHANCED ERYTHROPOIESIS AND IRON METABOLISMPharmaceuticalsFibroGen, Inc.
Mar 7, 20242024/0076364CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIESPharmaceuticalsFibroGen, Inc.
Jan 4, 20242024/0002344COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITIONOrganic fine chemistryFibroGen, Inc.
Jan 19, 20232023/0019602METHODS FOR TREATMENT OF MOTOR NEURON DISEASESPharmaceuticalsFibroGen, Inc.
May 19, 20222022/0151581METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSISMedical technologyFibroGen, Inc.
May 12, 20222022/0144931METHODS OF TREATMENT OF MUSCULAR DYSTROPHIESPharmaceuticalsFibroGen, Inc.
Feb 24, 20222022/0054474PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITORPharmaceuticalsFibroGen, Inc.
Dec 2, 20212021/0369702METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASEPharmaceuticalsFibroGen, Inc.
Sep 30, 20212021/0301006METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROMEPharmaceuticalsFibroGen, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KYNB · research, not advice